 |
12 Diseases |  |
1 Trial |
|
1 Trial |  |
156 News |  |
| «123» |
- ||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed, Monotherapy: Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) (clinicaltrials.gov) - Aug 21, 2017
P4, N=180, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting
- | Marizev (omarigliptin) / Merck (MSD)
Trial termination: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Apr 7, 2017
P3, N=4202, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed, Trial primary completion date: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Feb 23, 2017
P3, N=4202, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated; The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin Terminated --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2017
- |||| Marizev (omarigliptin) / Merck (MSD)
Enrollment open, Monotherapy: Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) (clinicaltrials.gov) - Nov 4, 2016
P4, N=180, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Terminated --> Active, not recruiting | Trial primary completion date: May 2016 --> Feb 2017 Not yet recruiting --> Recruiting
- ||||| Marizev (omarigliptin) / Merck (MSD)
New P4 trial, Monotherapy: Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039) (clinicaltrials.gov) - Sep 20, 2016
P4, N=180, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Marizev (omarigliptin) / Merck (MSD)
Trial termination, Trial primary completion date: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - May 21, 2016
P3, N=4202, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated | Trial primary completion date: Dec 2020 --> May 2016; The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (clinicaltrials.gov) - Apr 7, 2016
P3, N=402, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated | Trial primary completion date: Dec 2020 --> May 2016; The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin Active, not recruiting --> Completed
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Trial completion: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (clinicaltrials.gov) - Feb 3, 2016
P3, N=213, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Trial completion: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ?18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) (clinicaltrials.gov) - Sep 25, 2015
P3, N=203, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Marizev (omarigliptin) / Merck (MSD)
Trial primary completion date: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Aug 19, 2015
P3, N=4202, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Dec 2020
- Marizev (omarigliptin) / Merck (MSD)
Trial primary completion date: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ?18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) (clinicaltrials.gov) - Jul 15, 2015
P3, N=200, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2017 --> Dec 2020 Trial primary completion date: Mar 2016 --> Sep 2015
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Trial completion, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - Jul 2, 2015
P3, N=329, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2016 --> Sep 2015 Active, not recruiting --> Completed
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ?18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) (clinicaltrials.gov) - Apr 16, 2015
P3, N=200, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) (clinicaltrials.gov) - Feb 10, 2015
P3, N=751, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Combination therapy: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) (clinicaltrials.gov) - Jan 20, 2015
P3, N=307, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed: A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) (clinicaltrials.gov) - Jan 9, 2015
P3, N=210, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Marizev (omarigliptin) / Merck (MSD)
Trial primary completion date: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Dec 24, 2014
P3, N=4000, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2019 --> Oct 2017
- ||||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
Clinical: Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) (clinicaltrials.gov) - Dec 13, 2014
P3, N=642, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jul 2019 --> Oct 2017 Active, not recruiting --> Completed
- |||| Marizev (omarigliptin) / Merck (MSD)
Trial primary completion date, Journal: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Dec 6, 2014
P3, N=4000, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Jul 2019
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Nov 3, 2014
P3, N=4000, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Oct 2017 --> Jul 2019 Recruiting --> Active, not recruiting
- |||| Marizev (omarigliptin) / Merck (MSD)
Enrollment status: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Oct 21, 2014
P3, N=4000, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Recruiting
- | Marizev (omarigliptin) / Merck (MSD)
Trial initiation date: A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018) (clinicaltrials.gov) - Aug 30, 2014
P3, N=4000, Ongoing, Sponsor: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Recruiting --> Recruiting Initiation date: Oct 2012 --> Jan 2013
- |||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
Clinical: Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) (clinicaltrials.gov) - Jun 12, 2014
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Initiation date: Oct 2012 --> Jan 2013 Trial primary completion date: Feb 2015 --> Nov 2014
- |||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (clinicaltrials.gov) - Jun 10, 2014
P3, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Feb 2015 --> Nov 2014 Trial primary completion date: Mar 2016 --> Jan 2017
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - Jun 10, 2014
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Mar 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- ||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
Clinical: Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) (clinicaltrials.gov) - May 29, 2014
P3, N=600, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||||| Marizev (omarigliptin) / Merck (MSD)
Trial completion, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (clinicaltrials.gov) - May 28, 2014
P3, N=585, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (clinicaltrials.gov) - May 18, 2014
P3, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial completion date: Mar 2016 --> Jan 2017
- ||||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
Trial completion, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) (clinicaltrials.gov) - May 11, 2014
P3, N=414, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Mar 2016 --> Jan 2017 Active, not recruiting --> Completed
- |||| Marizev (omarigliptin) / Merck (MSD)
Trial primary completion date, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - May 1, 2014
P3, N=300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Jun 2015
- ||| Marizev (omarigliptin) / Merck (MSD)
Trial completion date, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - May 1, 2014
P3, N=300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2015 --> Jun 2015 Trial completion date: Apr 2015 --> Jun 2015
- |||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment open, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - May 1, 2014
P3, N=300, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Apr 2015 --> Jun 2015 Active, not recruiting --> Recruiting
- | Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027) (clinicaltrials.gov) - Apr 28, 2014
P3, N=65, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Active, not recruiting --> Terminated
- | Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027) (clinicaltrials.gov) - Apr 28, 2014
P3, N=65, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Terminated N=680 --> 65
- ||||| Marizev (omarigliptin) / Merck (MSD)
Combination therapy: Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022) (clinicaltrials.gov) - Apr 27, 2014
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=680 --> 65 Recruiting --> Active, not recruiting
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment change, Monotherapy: A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011) (clinicaltrials.gov) - Apr 1, 2014
P3, N=300, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=400 --> 300
- ||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (clinicaltrials.gov) - Mar 17, 2014
P3, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=400 --> 300 Recruiting --> Active, not recruiting
- | Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027) (clinicaltrials.gov) - Mar 13, 2014
P3, N=680, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (clinicaltrials.gov) - Mar 9, 2014
P3, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting N=500 --> 400
- ||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016) (clinicaltrials.gov) - Dec 22, 2013
P3, N=680, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=500 --> 400 Recruiting --> Active, not recruiting
- || Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027) (clinicaltrials.gov) - May 27, 2013
P3, N=680, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment open: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ?18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) (clinicaltrials.gov) - May 15, 2013
P3, N=200, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
Clinical: Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026) (clinicaltrials.gov) - Apr 24, 2013
P3, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| Marizev (omarigliptin) / Merck (MSD)
Enrollment closed, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (clinicaltrials.gov) - Apr 10, 2013
P3, N=568, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Marizev (omarigliptin) / Merck (MSD)
Trial completion: A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006) (clinicaltrials.gov) - Apr 10, 2013
P2b, N=685, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Januvia (sitagliptin) / Merck (MSD), Marizev (omarigliptin) / Merck (MSD)
Enrollment closed, Monotherapy: Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020) (clinicaltrials.gov) - Mar 28, 2013
P3, N=410, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
New P3 trial: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ?18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028) (clinicaltrials.gov) - Mar 18, 2013
P3, N=200, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Marizev (omarigliptin) / Merck (MSD)
Trial completion: A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031) (clinicaltrials.gov) - Mar 13, 2013
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Marizev (omarigliptin) / Merck (MSD)
New P1 trial: A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031) (clinicaltrials.gov) - Jan 10, 2013
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Marizev (omarigliptin) / Merck (MSD)
Clinical: A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024) (clinicaltrials.gov) - Dec 20, 2012
P3, N=400, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.